[ad_1]
(MedPage Today) — Tetramethylpyrazine nitrone was safe for people with amyotrophic lateral sclerosis (ALS), but neither a high nor low daily dose of the drug outperformed placebo for the primary outcome in a phase II trial in China.
At 180 days…
[ad_2]
Source link : https://www.medpagetoday.com/neurology/generalneurology/114420
Author :
Publish date : 2025-02-27 21:55:46
Copyright for syndicated content belongs to the linked Source.
Novel Agent Safe in ALS, Phase II Study Suggests
Related Posts
